Oncology Update: ADCETRIS(TM) Brentuximab Vedotin

We have completed our preliminary assessment of the FDA approved oncology drug ADCETRIS (TM) Brentuximab Vedotin using BioHorizon’s proprietary assessment methodology and have designated this oncology therapeutic agent as High Impact.  Given the observed treatment effect in pivotal clinical trials we see potential for rapid uptake by oncologists responsible for treating the indicated patient populations.  As with all High Impact therapeutics we recommend that our clients’ organization specific reimbursement and list/don’t list formulary decision making activities should be expedited.  We will update client’s as more data becomes available.